SAHA
Dotaz
Zobrazit nápovědu
- Klíčová slova
- DIANE'35',
- MeSH
- alopecie etiologie farmakoterapie MeSH
- androgeny fyziologie MeSH
- antagonisté androgenů MeSH
- cyproteron MeSH
- flutamid MeSH
- hirzutismus farmakoterapie MeSH
- lidé MeSH
- spironolakton MeSH
- Check Tag
- lidé MeSH
While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Moreover, decrease of survivin expression level is accompanied by its delocalization from centromere-related position in mitotic cells suggesting that both antiapoptotic and cell cycle regulation roles of survivin are affected by DAC + SAHA action. Addition of subtoxic concentration of all-trans-retinoic acid (ATRA) increases the efficiency of DAC + SAHA combination on viability, apoptosis induction, and ROS generation in HL-60 cells but has no effect in CML-T1 cell line. Peripheral blood lymphocytes from healthy donors showed no damage induced by DAC + SAHA + ATRA combination. Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization.
- MeSH
- apoptóza účinky léků MeSH
- azacytidin analogy a deriváty toxicita MeSH
- down regulace účinky léků MeSH
- HL-60 buňky MeSH
- inhibitory apoptózy metabolismus MeSH
- kontrolní body fáze G2 buněčného cyklu účinky léků MeSH
- kontrolní body M fáze buněčného cyklu účinky léků MeSH
- kyseliny hydroxamové toxicita MeSH
- lidé MeSH
- lymfocyty cytologie účinky léků imunologie MeSH
- nádorové buněčné linie MeSH
- nádorový supresorový protein p53 nedostatek genetika MeSH
- protinádorové antimetabolity farmakologie MeSH
- reaktivní formy kyslíku metabolismus MeSH
- synergismus léků MeSH
- tretinoin farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) which is being introduced into clinic for the treatment of hematological diseases. We studied the effect of this compound on six human hematopoietic cell lines (JURL-MK1, K562, CML-T1, Karpas-299, HL-60, and ML-2) as well as on normal human lymphocytes and on leukemic primary cells. SAHA induced dose-dependent and cell type-dependent cell death which displayed apoptotic features (caspase-3 activation and apoptotic DNA fragmentation) in most cell types including the normal lymphocytes. At subtoxic concentrations (0.5-1 microM), SAHA increased the cell adhesivity to fibronectin (FN) in all leukemia/lymphoma-derived cell lines but not in normal lymphocytes. This increase was accompanied by an enhanced expression of integrin beta1 and paxillin, an essential constituent of focal adhesion complexes, both at the protein and mRNA level. On the other hand, the inhibition of ROCK protein, an important regulator of cytoskeleton structure, had no consistent effect on SAHA-induced increase in the cell adhesivity. The promotion of cell adhesivity to FN seems to be specific for SAHA as we observed no such effects with other HDAC inhibitors (trichostatin A and sodium butyrate).
- MeSH
- antigeny CD29 MeSH
- apoptóza MeSH
- buněčná adheze účinky léků MeSH
- fibronektiny metabolismus MeSH
- kyseliny hydroxamové farmakologie MeSH
- leukemie metabolismus MeSH
- lidé MeSH
- lymfocyty metabolismus účinky léků MeSH
- nádorové buněčné linie MeSH
- paxilin metabolismus MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- protinádorové látky farmakologie MeSH
- průtoková cytometrie MeSH
- separace buněk MeSH
- western blotting MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Epigenetic therapy reverting aberrant acetylation or methylation offers the possibility to target preferentially tumor cells and to preserve normal cells. Combination epigenetic therapy may further improve the effect of individual drugs. We investigated combined action of demethylating agent decitabine and histone deacetylase inhibitor SAHA (Vorinostat) on different leukemic cell lines in comparison with peripheral blood lymphocytes. Large decrease of viability, as well as huge p21WAF1 induction, reactive oxygen species formation, and apoptotic features due to combined decitabine and SAHA action were detected in leukemic cell lines irrespective of their p53 status, while essentially no effect was observed in response to the combined drug action in normal peripheral blood lymphocytes of healthy donors. p53-dependent apoptotic pathway was demonstrated to participate in the wtp53 CML-T1 leukemic cell line response, while significant influence of reactive oxygen species on viability decrease has been detected in p53-null HL-60 cell line.
- MeSH
- apoptóza účinky léků MeSH
- azacytidin aplikace a dávkování analogy a deriváty MeSH
- kultivované buňky MeSH
- kyseliny hydroxamové aplikace a dávkování MeSH
- leukemie farmakoterapie patologie patofyziologie MeSH
- lidé MeSH
- lymfocyty cytologie účinky léků fyziologie MeSH
- protinádorové antimetabolity aplikace a dávkování MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Restoration of cellular apoptotic pathways plays a crucial role in cancer therapy strategies. In a broad spectrum of anticancer drugs, epigenetic effectors are in the center of interest mostly because of potential reversibility of their action. Methylation status of the cells is influenced by methyltransferase inhibitor 2-deoxy-5'-azacytidine (decitabine, DAC), but higher concentrations of this agent cause a DNA-damage. In our study, tumor supressor p53-apoptotic pathway was activated in decitabine-induced cell death. Expression of p53-inducible BH3-only apoptotic proteins Puma and Noxa was elevated and large activation of executive caspases was observed. The extent of acetylation in the cell is affected by histonedeacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Combination of SAHA with decitabine brought synergistic effect on apoptosis triggering in CML-T1 cell line, but apoptosis as well as necrosis occurred also in normal peripheral blood lymphocytes. Therefore, promising potential of such combined therapy calls for more detailed investigation of unwanted effects in normal cells.
- MeSH
- apoptóza účinky léků genetika MeSH
- azacytidin analogy a deriváty farmakologie MeSH
- chronická myeloidní leukemie genetika metabolismus patologie MeSH
- kultivované buňky MeSH
- kyseliny hydroxamové farmakologie MeSH
- lidé MeSH
- lymfocyty účinky léků metabolismus MeSH
- preklinické hodnocení léčiv MeSH
- proteiny regulující apoptózu genetika metabolismus MeSH
- protinádorové antimetabolity farmakologie MeSH
- protokoly protinádorové kombinované chemoterapie farmakologie MeSH
- protoonkogenní proteiny c-bcl-2 genetika metabolismus MeSH
- protoonkogenní proteiny genetika metabolismus MeSH
- regulace genové exprese u leukemie účinky léků MeSH
- synergismus léků MeSH
- upregulace účinky léků genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
2nd ed. xv, 253 s. : il.
- MeSH
- nukleární lékařství MeSH
- Publikační typ
- příručky MeSH
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- radiologie, nukleární medicína a zobrazovací metody
2nd ed. 80 s. : il.